Description
Enzymes (PI3K and PTEN) controlling cellular levels of 3-phosphorylated phosphoinositides are known as important drivers or suppressors of tumorigenesis in various cancers. In this issue of Cancer Discovery, the laboratories of Sasaki and Pandolfi identify the lipid phosphatase INPP4B as a context-specific tumor suppressor that controls phosphoinositide levels and AKT2 activation in PTEN-deficient cells.
Increased signaling through phosphoinositide 3-kinases (PI3Ks) is considered an oncogenic driver in cancer. Consequently, targeting enzymes in this network has been a major goal of cancer drug development (1) . Much attention has focused on class I PI3Ks (PI3Kα, P3Kβ, PI3Kδ and PI3Kγ) that convert phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) to PtdIns (3, 4, 5) trisphosphate (PtdIns(3,4,5)P 3 , hereafter abbreviated PIP 3 ) (Fig. 1) . Encouragingly, the first PI3K-targeted therapy (idelalisib, a PI3Kδ-selective agent) achieved regulatory approval recently for treatment of certain blood cancers (2) .
Compounds targeting other members of the class I PI3K family, or targeting downstream protein kinases including AKT and mTOR are in various phases of clinical trials (1) . In addition to PI3Ks, there are numerous enzymes that modulate levels of 3-phosphorylated phosphoinositides in cells and therefore may play an important role in cancer. The PIP 3 phosphatase PTEN (Fig. 1) is frequently deleted or inactivated in human cancer, but strategies to target PTEN-deficient tumors rely mainly on blocking PI3K or downstream kinases. In this issue of Cancer Discovery, the groups of Sasaki (3) and Pandolfi (4) identify the lipid phosphatase INPP4B as a tumor suppressor that controls the levels of PI3K lipid products and is potentially targetable in aggressive human thyroid cancers.
INPP4B is an inositol phospholipid phosphatase that is best known for dephosphorylating the 4'-hydroxyl of PtdIns(3,4)P 2 to produce PtdIns(3)P (Fig. 1, top) .
Since AKT kinases can be recruited to membranes and activated by either PIP 3 or PtdIns(3,4)P 2 , the loss of INPP4B would be predicted to elevate AKT activity and promote transformation. Indeed, growing evidence has pointed to human INPP4B as a potential tumor suppressor gene. Gewinner and colleagues found loss of heterozygosity at the INPP4B locus in many basal-like breast cancer and ovarian cancers (5) . Moreover, they found that knockdown of INPP4B enhanced AKT activation, anchorage-independent growth and cell motility. Correspondingly, Fedele and colleagues showed that expression of INPP4B in ER-negative and INPP4B-negative human breast cancer cells reduced AKT activity and anchorage-independent growth (6). Interestingly, INPP4B protein loss was frequently found in tumors that also lacked PTEN (6) . Later studies provided further evidence for reduced INPP4B expression in cancer (7, 8) . However, the tumor suppressor activity of INPP4B had yet to be proven or studied mechanistically in a mouse model.
The Sasaki lab generated Inpp4b Interestingly, they identify a likely role for PI3K-C2α, a class II PI3K that can generate PtdIns(3,4)P 2 from PtdIns(4)P but cannot directly produce PIP 3 . According to this model, Lastly, the studies discussed here were not able to evaluate the role Inpp4b loss in breast and ovarian cancer, since Pten +/-Inpp4b -/-mice succumbed to thyroid tumors at an early age. It will be particularly interesting to resolve the role of INPP4B in breast cancer,
given that Toker and colleagues recently reported that INPP4B has oncogenic potential in breast cancer by promoting SGK3 activation (Fig. 1, top) (10) . Future studies applying tissue-specific deletion of Inpp4b should shed light on the role of this phosphatase in controlling tumor progression and metastasis in other contexts.
Figure Legend
Model mechanisms of how INPP4B acts as a tumor suppressor by reducing AKT2
activation. In the classical model INPP4B reduces PtdIns(3,4)P 2 at the plasma membrane.
